Allarity Therapeutics, Inc. (NASDAQ:ALLR) Short Interest Down 45.4% in August

Allarity Therapeutics, Inc. (NASDAQ:ALLR) was the target of a significant drop in short interest in August. As of August 15th, there was short interest totalling 299,300 shares, a drop of 45.4% from the July 31st total of 547,800 shares. Based on an average daily volume of 5,860,000 shares, the short-interest ratio is presently 0.1 days. Currently, 0.7% of the shares of the stock are sold short.

Allarity Therapeutics Price Performance

ALLR opened at $0.16 on Friday. Allarity Therapeutics has a 52-week low of $0.14 and a 52-week high of $38.20. The firm’s fifty day simple moving average is $0.19 and its two-hundred day simple moving average is $2.47.

Allarity Therapeutics (NASDAQ:ALLR) last posted its quarterly earnings data on Monday, August 5th. The company reported ($0.11) earnings per share (EPS) for the quarter. Equities research analysts expect that Allarity Therapeutics will post -2.6 EPS for the current year.

Allarity Therapeutics Company Profile

Allarity Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA (ixabepilone), a selective microtubule inhibitor in phase 2 for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme.